Clinical trials: Cancer, Advanced
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma.
- Trial name
- NCT04674683
- Testing
- HBI-8000 in combination with nivolumab
- Where
- 139 sites in United States, Australia and 15 more
- Volunteers
- 450 people
- Sponsor
- HUYABIO International, LLC.
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
This phase I trial is studying the side effects and best dose of bevacizumab and cediranib maleate in treating patients with metastatic or unresectable solid tumor, lymphoma, intracranial glioblastoma, gliosarcoma or anaplastic…
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00458731
- Testing
- bevacizumab, cediranib maleate
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Soft Tissue Sarcoma
Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.
In this open, single center, one- armed clinical study, enrolled patients will receive the following treatment: 300 mg/m2 of nab-paclitaxel (Hengrui Pharmaceutical, Lianyungang, China) and 200 mg of PD-1 inhibitor (camrelizumab…
- Trial name
- NCT05189483
- Testing
- Albumin-Bound Paclitaxel, Camrelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Radiation Pneumonitis
The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia
Radiation pneumonitis (RP) is a common complication of radiotherapy for thoracic tumors, and the incidence rate of grade 2 or above RP is 20% -40%; The use of antibiotics after secondary bacterial infection due to radiation…
- Trial name
- NCT06079931
- Testing
- Babaodan Capsule
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Esophageal Cancer
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer
The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced or recurrent esophageal cancer who have completed the previous Phase 2 study (CA139-540) and who should continue on therapy with…
- Trial name
- NCT00971841
- Testing
- Paclitaxel
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb
Neoplasm
Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer
Patients undergoing immunotherapy for advanced cancer under IRB-approved protocols, who are to receive immune cells in adoptive transfer, will have less than or equal to 50% of those cells labeled with In-111-oxine and…
- Trial name
- NCT00026897
- Testing
- Gamma-camera imaging, Low-risk biopsy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Irinotecan (Camptosar) in Patients With Advanced Sarcomas
Primary Objectives: 1. To determine the efficacy of the topoisomerase I (topo I) inhibitor irinotecan, delivered via a low-dose protracted schedule to patients with advanced sarcoma. 2.
- Trial name
- NCT00509860
- Testing
- Irinotecan
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma, HER-2 Protein Overexpression
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
The purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or nivolumab), to learn what the side effects are, and to see whether this…
- Conditions
- Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma
- Trial name
- NCT04995003
- Testing
- T cells or CAR T cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
Metastatic Castration-resistant Prostate Cancer, Bone Metastases
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
This is an observational study in which data from Chinese men with metastatic castration-resistant prostate cancer that has spread to the bones and who start Radium-223 therapy is studied.
- Trial name
- CREDIT (NCT05301062)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Bayer
Acceptance and Commitment Therapy, Mental Health, Cognitive Impairment,Colorectal Cancer
Effect of Acceptance and Commitment Therapy Based Interventions on Mental Health and Cognitive Impairment for Patients With Advanced Colorectal Cancer
The present study aims to: Determine the effect of acceptance and commitment therapy-based interventions on mental health and cognitive impairment for patients with advanced colorectal cancer.
- Trial name
- NCT05741255
- Testing
- Acceptance and Commitment Therapy
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alexandria University
Breast Cancer
Uncovering Potential Breast Cancer Biomarkers Amp; Possible Drug Targets Using Advanced Quantitative Mass Spectrometry
The purpose of this study is to evaluate the use of advanced quantitative mass spectometry (Super SILAC) as a discovery platform to uncover novel protein biomarkers in tumor and to compare the protein profile between different…
- Trial name
- NCT01619514
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Cancer
Multiple Ascending Dose of BMS-911543
The purpose of this first in human study is to determine if BMS-911543 is safe and tolerable in subjects with symptomatic intermediate-1, intermediate-2 or high risk myelofibrosis to permit clinical testing at the Maximum…
- Trial name
- NCT01236352
- Testing
- BMS-911543
- Where
- 5 sites in United States, Australia
- Volunteers
- 98 people
- Sponsor
- Bristol-Myers Squibb
Colonic Polyp, Colon Adenoma
Colonoscopic Adenoma and Advanced Neoplasia Detection Rates According to Age
Current recommendations for colonoscopy screening programs usually involve patients older than 50 years of age. However, little is known about polyp or adenoma detection rates under 50.
- Conditions
- Colonic Polyp, Colon Adenoma, Colonoscopy, Colon Cancer
- Trial name
- NCT03361904
- Testing
- Colonoscopy
- Volunteers
- 6,027 people
- Sponsor
- Société Française d'Endoscopie Digestive
Recurrent Renal Cell Cancer, Renal Cell Carcinoma
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
This phase I/randomized phase II trial is studying the side effects and best dose of bevacizumab and to see how well it works when given together with or without MEDI-522 in treating patients with unresectable or metastatic…
- Conditions
- Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00684996
- Testing
- etaracizumab, bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
HER2-positive Advanced Gastric Cancer
Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy
This is a multicenter, open-label, prospective, phase 2 study of trastuzumab, bevacizumab, and paclitaxel as second-line treatment for patients with HER2-positive advanced gastric cancer who had progressed on first-line…
- Trial name
- TREAZURE (NCT05640830)
- Testing
- trastuzumab, bevacizumab with paclitaxel (triple combination)
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Kangbuk Samsung Hospital
Unspecified Childhood Solid Tumor, Protocol Specific
Bortezomib in Treating Children With Advanced Solid Tumors
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of bortezomib in treating children who have advanced solid tumors that have not…
- Trial name
- NCT00021216
- Testing
- bortezomib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Solid Tumors
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
This is a Phase 1/1B, non-randomized, open-label, dose-escalation study of robatumumab (SCH 717454, MK-7454) administered in combination with chemotherapy in pediatric participants with solid tumors, to be conducted in…
- Conditions
- Neoplasms, Solid Tumors, Bone Cancer, Kidney Tumor
- Trial name
- NCT00960063
- Testing
- Temozolomide, Vincristine, Ifosfamide
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced Non Small Cell Lung Cancer
Sleep Apnea and Lung Cancer
cases of locally advanced non small cell lung cancer (diagnosed by PET/CT scan and histopathological confirmation) will be screened for sleep disorders by Epworth sleepiness scale then confirmed by full night polysomnographic…
- Trial name
- NCT03741647
- Testing
- sleep study and blood sample
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Zagazig University
Breast Cancer
T-DM1 in HER2-positive Metastatic/Relapsed Breast Cancer
This is a retrospective, multicenter, non-interventional study for the evaluation of real-world efficacy and safety of T-DM1 in metastatic/relapsed HER2-positive breast cancer as part of the establishment of hospital medical…
- Trial name
- NCT04202328
- Where
- 60 sites in South Korea
- Volunteers
- 1,000 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma (HCC)
TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with Tislelizumab and Lenvatinib in patients with advanced-stage hepatocellular carcinoma (HCC).
- Trial name
- CHANCE2602 (NCT07836309)
- Where
- China
- Volunteers
- 596 people
- Sponsor
- Zhongda Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.